GlobeNewswire - Industry News on Pharmaceuticals http://www.yebxqs.cn/RssFeed/industry/4577-Pharmaceuticals/feedTitle/GlobeNewswire%20-%20Industry%20News%20on%20Pharmaceuticals Contains the last 20 releases newsdesk@globenewswire.com (NewsDesk) Wed, 03 Mar 2021 01:25:00 GMT webmaster@globenewswire.com (Webmaster) http://www.yebxqs.cn/news-release/2021/03/03/2185798/0/en/Morphic-Therapeutic-Announces-Pricing-of-Upsized-245-0-Million-Public-Offering.html http://www.yebxqs.cn/news-release/2021/03/03/2185798/0/en/Morphic-Therapeutic-Announces-Pricing-of-Upsized-245-0-Million-Public-Offering.html Nasdaq:MORF US61775R1059 Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share. The gross proceeds from this offering are expected to be approximately $245.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Morphic. The offering is expected to close on or about March 5, 2021, subject to the satisfaction of customary closing conditions. Morphic has also granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by Morphic.

]]>
Wed, 03 Mar 2021 01:25 GMT 2185798 en GlobeNewswire Inc. Morphic Therapeutic Wed, 03 Mar 2021 01:25 GMT Stock Market News
http://www.yebxqs.cn/news-release/2021/03/02/2185732/0/en/Nurix-Therapeutics-Announces-Launch-of-Proposed-Public-Offering-of-Common-Stock.html http://www.yebxqs.cn/news-release/2021/03/02/2185732/0/en/Nurix-Therapeutics-Announces-Launch-of-Proposed-Public-Offering-of-Common-Stock.html Nasdaq:NRIX US67080M1036 Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares of common stock are being offered by Nurix. In addition, Nurix intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock.

]]>
Tue, 02 Mar 2021 21:15 GMT 2185732 en GlobeNewswire Inc. Nurix Therapeutics, Inc. Tue, 02 Mar 2021 21:16 GMT Stock Market News Protein degradation financing
http://www.yebxqs.cn/news-release/2021/03/02/2185706/0/en/Lumos-Pharma-to-Present-Poster-Demonstrating-Greater-GH-Response-to-LUM-201-than-to-Standard-GH-Secretagogues-in-PGHD-at-the-Endocrine-Society-ENDO-2021-Annual-Meeting.html http://www.yebxqs.cn/news-release/2021/03/02/2185706/0/en/Lumos-Pharma-to-Present-Poster-Demonstrating-Greater-GH-Response-to-LUM-201-than-to-Standard-GH-Secretagogues-in-PGHD-at-the-Endocrine-Society-ENDO-2021-Annual-Meeting.html Nasdaq:LUMO US55028X1090 Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting AUSTIN, Texas, March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at the virtual Endocrine Society 2021 Annual Meeting, March 20th-23rd. “LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency” will be presented by authors Bright, G., MD, et al. on Saturday, March 20, 2021, at 11:00AM ET in Session P33 – “Growth and Growth Hormone.” At that time, the poster can be accessed in the “Investors & Media” section of our website on the “Posters & Presentations” page under “Events & Presentations.”

]]>
Tue, 02 Mar 2021 21:05 GMT 2185706 en GlobeNewswire Inc. Lumos Pharma, Inc. Tue, 02 Mar 2021 21:05 GMT Health Product / Services Announcement BIOTECHNOLOGY HEALTH MEDICAL PHARMACEUTICALS
http://www.yebxqs.cn/news-release/2021/03/02/2185711/0/en/PLx-Pharma-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html http://www.yebxqs.cn/news-release/2021/03/02/2185711/0/en/PLx-Pharma-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html Nasdaq:PLXP US72942A1079 PLx Pharma Inc. Announces Proposed Public Offering of Common Stock SPARTA, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard? drug delivery platform designed to provide more effective and safer products, announced today that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by PLx.

]]>
Tue, 02 Mar 2021 21:05 GMT 2185711 en GlobeNewswire Inc. PLx Pharma Inc. Tue, 02 Mar 2021 21:05 GMT Initial Public Offerings
http://www.yebxqs.cn/news-release/2021/03/02/2185629/0/en/Recording-of-the-Fourth-Quarter-2020-Investor-Conference-Webinar.html http://www.yebxqs.cn/news-release/2021/03/02/2185629/0/en/Recording-of-the-Fourth-Quarter-2020-Investor-Conference-Webinar.html Riga:OLF1R LV0000100501 Recording of the Fourth Quarter 2020 Investor Conference Webinar On March 2, 2021 JSC Olainfarm organized its Investor Conference Online Webinar. During the webinar Chairperson of Management Board Jeroen Weites and member of the management board Zane Kotāne?analyzed the financial results of fourth quarter and 12 months 2020 and informed about other recent activities within the company.

]]>
Tue, 02 Mar 2021 18:05 GMT 2185629 en GlobeNewswire Inc. Olainfarm Tue, 02 Mar 2021 18:05 GMT Regulatory information European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185629/0/lv/Ir-nosl%C4%93gusies-Olainfarm-2020-gada-4-ceturk%C5%A1%C5%86a-virtu%C4%81l%C4%81-konference.html http://www.yebxqs.cn/news-release/2021/03/02/2185629/0/lv/Ir-nosl%C4%93gusies-Olainfarm-2020-gada-4-ceturk%C5%A1%C5%86a-virtu%C4%81l%C4%81-konference.html Riga:OLF1R LV0000100501 Ir noslēgusies Olainfarm 2020. gada 4. ceturk??a virtuālā konference ?.g. 2. martā AS ?Olainfarm” aizvadīja virtuālo konferenci investoriem. Konferences laikā AS ?Olainfarm” valdes priek?sēdētājs Jerūns Veitess (Jeroen Weites) un valdes locekle Zane Kotāne analizēja 2020. gada 4. ceturk??a un 12 mēne?u finan?u rezultātus, kā arī informēja par citām aktualitātēm uz?ēmumā.

]]>
Tue, 02 Mar 2021 18:05 GMT 2185629 lv GlobeNewswire Inc. Olainfarm Tue, 02 Mar 2021 18:05 GMT Regulatory information European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185588/0/en/Number-of-voting-rights-as-of-February-28-2021.html http://www.yebxqs.cn/news-release/2021/03/02/2185588/0/en/Number-of-voting-rights-as-of-February-28-2021.html Paris:COX FR0013018124 Number of voting rights as of February 28, 2021 Nicox SA
Société anonyme with a registered capital of € 37,103,985

]]>
Tue, 02 Mar 2021 16:45 GMT 2185588 en GlobeNewswire Inc. NICOX Tue, 02 Mar 2021 16:45 GMT Company Announcement European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185588/0/fr/Nombre-de-droits-de-vote-au-28-f%C3%A9vrier-2021.html http://www.yebxqs.cn/news-release/2021/03/02/2185588/0/fr/Nombre-de-droits-de-vote-au-28-f%C3%A9vrier-2021.html Paris:COX FR0013018124 Nombre de droits de vote au 28 février 2021 Nicox SA

]]>
Tue, 02 Mar 2021 16:45 GMT 2185588 fr GlobeNewswire Inc. NICOX Tue, 02 Mar 2021 16:45 GMT Company Announcement European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185465/0/en/Novartis-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Annual-General-Meeting.html http://www.yebxqs.cn/news-release/2021/03/02/2185465/0/en/Novartis-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Annual-General-Meeting.html SWX:NOVN LSE:68CT CH0012005267 XS0432810116 2889 Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting Basel, March 2, 2021 — Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the Group’s Annual General Meeting (AGM). In accordance with the Swiss COVID-19 Ordinance 3, the 2021 AGM was held without shareholders being physically present. Accordingly, shareholders exercised their shareholder rights via the Independent Proxy and could follow the AGM via a live webcast. In addition, shareholders had the opportunity to send their questions to the Board of Directors electronically in advance, with the most important questions being answered by the Chairman and the CEO during the AGM.

]]>
Tue, 02 Mar 2021 14:26 GMT 2185465 en GlobeNewswire Inc. Novartis International AG Tue, 02 Mar 2021 14:26 GMT Company Announcement Media Release Reimagine Medicine Medical Innovations Future of Healthcare Media Release Reimagine Medicine Medical Innovations Future of Healthcare Media Release Reimagine Medicine Medical Innovations Future of Healthcare
http://www.yebxqs.cn/news-release/2021/03/02/2185465/0/de/Die-Aktion%C3%A4re-von-Novartis-heissen-an-der-Generalversammlung-alle-Antr%C3%A4ge-des-Verwaltungsrats-gut.html http://www.yebxqs.cn/news-release/2021/03/02/2185465/0/de/Die-Aktion%C3%A4re-von-Novartis-heissen-an-der-Generalversammlung-alle-Antr%C3%A4ge-des-Verwaltungsrats-gut.html SWX:NOVN LSE:68CT CH0012005267 XS0432810116 2889 Die Aktion?re von Novartis heissen an der Generalversammlung alle Antr?ge des Verwaltungsrats gut Basel, 2. M?rz 2021 – Die Aktion?re von Novartis stimmten heute an der Generalversammlung (GV) allen Vorschl?gen des Verwaltungsrats zu. Im Einklang mit der COVID-19-Verordnung?3 waren an der Generalversammlung 2021 vor Ort keine Aktion?re anwesend. Entsprechend übten die Aktion?re ihr Stimmrecht über den unabh?ngigen Stimmrechtsvertreter aus und konnten die Versammlung live per Webcast verfolgen. Zudem hatten die Aktion?re die M?glichkeit, ihre Fragen im Voraus elektronisch an den Verwaltungsrat zu senden, wobei der Verwaltungsratspr?sident und der CEO die wichtigsten Fragen w?hrend der GV beantworteten.

]]>
Tue, 02 Mar 2021 14:26 GMT 2185465 de GlobeNewswire Inc. Novartis International AG Tue, 02 Mar 2021 14:26 GMT Company Announcement Media Release Reimagine Medicine Medical Innovations Future of Healthcare Media Release Reimagine Medicine Medical Innovations Future of Healthcare Media Release Reimagine Medicine Medical Innovations Future of Healthcare
http://www.yebxqs.cn/news-release/2021/03/02/2185465/0/fr/Les-actionnaires-de-Novartis-approuvent-toutes-les-r%C3%A9solutions-propos%C3%A9es-par-le-Conseil-d-administration-lors-de-l-Assembl%C3%A9e-g%C3%A9n%C3%A9rale-annuelle.html http://www.yebxqs.cn/news-release/2021/03/02/2185465/0/fr/Les-actionnaires-de-Novartis-approuvent-toutes-les-r%C3%A9solutions-propos%C3%A9es-par-le-Conseil-d-administration-lors-de-l-Assembl%C3%A9e-g%C3%A9n%C3%A9rale-annuelle.html SWX:NOVN LSE:68CT CH0012005267 XS0432810116 2889 Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle Bale, le 2 mars 2021 — Les actionnaires de Novartis ont accepté ce jour les recommandations du Conseil d’administration pour toutes les résolutions proposées lors de l’Assemblée générale (AG) annuelle du groupe. Conformément à l’Ordonnance 3 suisse sur les mesures destinées à lutter contre le COVID-19, l’AG 2021 s’est tenue sans la présence physique des actionnaires. Les actionnaires ont donc exercé leurs droits via le représentant indépendant et ont pu suivre l’AG qui était retransmise en direct. Les actionnaires pouvaient également envoyer leurs questions au Conseil d’administration en amont, par voie électronique. Le Président du Conseil d’administration et le CEO ont répondu aux questions les plus importantes pendant l’AG.

]]>
Tue, 02 Mar 2021 14:26 GMT 2185465 fr GlobeNewswire Inc. Novartis International AG Tue, 02 Mar 2021 14:26 GMT Company Announcement Media Release Reimagine Medicine Medical Innovations Future of Healthcare Media Release Reimagine Medicine Medical Innovations Future of Healthcare Media Release Reimagine Medicine Medical Innovations Future of Healthcare
http://www.yebxqs.cn/news-release/2021/03/02/2185442/0/en/MediPharm-Labs-Announces-Increase-to-Bought-Deal-Equity-Financing-to-29-Million.html http://www.yebxqs.cn/news-release/2021/03/02/2185442/0/en/MediPharm-Labs-Announces-Increase-to-Bought-Deal-Equity-Financing-to-29-Million.html TSX:LABS Other OTC:MEDIF Frankfurt:MLZ CA58504D1006 MediPharm Labs Announces Increase to Bought Deal Equity Financing to $29 Million NOT FOR DISTRIBUTION TO?UNITED STATES?NEWSWIRE SERVICES OR FOR DISSEMINATION IN?THE UNITED STATES

]]>
Tue, 02 Mar 2021 14:13 GMT 2185442 en GlobeNewswire Inc. MediPharm Labs Corp. Tue, 02 Mar 2021 14:14 GMT Company Announcement Financing Agreements
http://www.yebxqs.cn/news-release/2021/03/02/2185399/0/en/Harrow-Health-to-Participate-in-H-C-Wainwright-Global-Life-Sciences-Conference.html http://www.yebxqs.cn/news-release/2021/03/02/2185399/0/en/Harrow-Health-to-Participate-in-H-C-Wainwright-Global-Life-Sciences-Conference.html Nasdaq:HROW US4158581094 Harrow Health to Participate in H.C. Wainwright Global Life Sciences Conference NASHVILLE, Tenn., March 02, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C.?Wainwright Global Life Sciences Conference to be held virtually on March?9-10, 2021.

]]>
Tue, 02 Mar 2021 14:00 GMT 2185399 en GlobeNewswire Inc. Harrow Health, Inc. Tue, 02 Mar 2021 14:01 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/03/02/2185313/0/en/Zosano-Pharma-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html http://www.yebxqs.cn/news-release/2021/03/02/2185313/0/en/Zosano-Pharma-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html Nasdaq:ZSAN US98979H1032 Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference FREMONT, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Life Sciences Conference which will be available on Tuesday, March 9, 2021 at 7:00 am ET.

]]>
Tue, 02 Mar 2021 13:30 GMT 2185313 en GlobeNewswire Inc. Zosano Pharma Corporation Tue, 02 Mar 2021 13:30 GMT Health Trade Show
http://www.yebxqs.cn/news-release/2021/03/02/2185294/0/en/Lowell-Farms-Inc-Formerly-Known-as-Indus-Holdings-Inc-Announces-Fourth-Quarter-and-Fiscal-Year-2020-Results.html http://www.yebxqs.cn/news-release/2021/03/02/2185294/0/en/Lowell-Farms-Inc-Formerly-Known-as-Indus-Holdings-Inc-Announces-Fourth-Quarter-and-Fiscal-Year-2020-Results.html CNSX:INDS.CN CNSX:LOWL.CN Other OTC:INDXF Other OTC:LOWLF CA45580N1024 Lowell Farms Inc., Formerly Known as Indus Holdings, Inc., Announces Fourth Quarter and Fiscal Year 2020 Results Vertically-Integrated Cannabis Leader Doubles Down on Path to Scalability and Self-Sustaining Profitability With a Renewed Go-Forward Strategy]]> Tue, 02 Mar 2021 13:07 GMT 2185294 en GlobeNewswire Inc. Indus Holdings, Inc. Tue, 02 Mar 2021 13:08 GMT Earnings Releases and Operating Results http://www.yebxqs.cn/news-release/2021/03/02/2185292/0/en/TRACON-Pharmaceuticals-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html http://www.yebxqs.cn/news-release/2021/03/02/2185292/0/en/TRACON-Pharmaceuticals-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html Nasdaq:TCON US89237H1005 TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

]]>
Tue, 02 Mar 2021 13:05 GMT 2185292 en GlobeNewswire Inc. TRACON Pharmaceuticals, Inc. Tue, 02 Mar 2021 13:05 GMT Health Trade Show
http://www.yebxqs.cn/news-release/2021/03/02/2185204/0/en/Alimera-Sciences-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html http://www.yebxqs.cn/news-release/2021/03/02/2185204/0/en/Alimera-Sciences-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html Nasdaq:ALIM US0162591038 Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Global Life Sciences Conference to be held on March 9-10, 2021.

]]>
Tue, 02 Mar 2021 13:00 GMT 2185204 en GlobeNewswire Inc. Alimera Sciences, Inc. Tue, 02 Mar 2021 13:00 GMT Health Trade Show #ALIM #HCW
http://www.yebxqs.cn/news-release/2021/03/02/2185235/0/en/Ayala-Pharmaceuticals-to-Participate-in-Upcoming-Virtual-Investor-Conferences.html http://www.yebxqs.cn/news-release/2021/03/02/2185235/0/en/Ayala-Pharmaceuticals-to-Participate-in-Upcoming-Virtual-Investor-Conferences.html Nasdaq:AYLA US05465V1089 Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences REHOVOT, Israel and WILMINGTON, Del., March 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will present at three upcoming virtual investor conferences:

]]>
Tue, 02 Mar 2021 13:00 GMT 2185235 en GlobeNewswire Inc. Ayala Pharmaceuticals Tue, 02 Mar 2021 13:01 GMT Calendar of Events Health
http://www.yebxqs.cn/news-release/2021/03/02/2185275/0/en/Enzo-Announces-its-GENFLEX-Molecular-Test-Detects-Current-COVID-19-Variants.html http://www.yebxqs.cn/news-release/2021/03/02/2185275/0/en/Enzo-Announces-its-GENFLEX-Molecular-Test-Detects-Current-COVID-19-Variants.html NYSE:ENZ US2941001024 Enzo Announces its GENFLEX? Molecular Test Detects Current COVID-19 Variants Results indicate that GENFLEX meets new FDA guidance calling for COVID-19 test developers to assess the impact of viral mutations on testing results

]]>
Tue, 02 Mar 2021 13:00 GMT 2185275 en GlobeNewswire Inc. Enzo Biochem, Inc. Tue, 02 Mar 2021 13:04 GMT Press releases Company Announcement Health
http://www.yebxqs.cn/news-release/2021/03/02/2185277/0/en/Kiniksa-Launches-Patient-Registry-RESONANCE-for-Recurrent-Pericarditis.html http://www.yebxqs.cn/news-release/2021/03/02/2185277/0/en/Kiniksa-Launches-Patient-Registry-RESONANCE-for-Recurrent-Pericarditis.html Nasdaq:KNSA BMG5269C1010 Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis Registry will continue to advance the understanding of the clinical outcomes and management of recurrent pericarditis in partnership with the healthcare community, patients and patient advocates]]> Tue, 02 Mar 2021 13:00 GMT 2185277 en GlobeNewswire Inc. Kiniksa Pharmaceuticals, Ltd. Tue, 02 Mar 2021 13:04 GMT Product / Services Announcement Recurrent Pericarditis RESONANCE Patient Registry
粉色午夜视频/色戒未删减版在线观看视频/44383x3全国最大的免费观看/冲田杏梨番号